Published February 14, 2026 | Version v1
Journal article Open

A STUDY ON DUCHENNE MUSCULAR DYSTROPHY: CLINICAL FEATURES AND DISEASE PROGRESSION

Authors/Creators

  • 1. P.S.V. College of Pharmaceutical Science and Research, Krishnagiri-635108.
  • 2. P.S.V. College of Pharmaceutical Science and Research, Krishnagiri-635108.3

Description

Duchenne Muscular Dystrophy (DMD) is a genetic disorder characterized by progressive muscle weakness and degeneration, primarily affecting boys. It is caused by mutations in the dystrophin gene. DMD leads to loss of muscle function, respiratory and cardiac complications, and reduced life expectancy. It primarily affects boys and usually appears in early childhood. Symptoms include difficulty walking, frequent falls, and heart and respiratory problems. Although there is no cure, treatments such as corticosteroids, gene therapy, and physiotherapy can slow disease progression and improve quality of life. Current management focuses on slowing disease progression, managing symptoms, and improving quality of life. On-going research explores innovative treatments and potential cures.

Files

31 WJPSR 2051.pdf

Files (1.0 MB)

Name Size Download all
md5:6c56f5d28959ad7458a62072de945c88
1.0 MB Preview Download

Additional details

References

  • 1. Deng J, Zhang J, Shi K, Liu Z. Drug development progress in duchenne muscular dystrophy. Frontiers in Pharmacology, 2022 Jul 22; 13: 950651
  • 2. Bladen CL, Salgado D, Monges S, Foncuberta ME, Kekou K, Kosma K, Dawkins H, Lamont L, Roy AJ, Chamova T, Guergueltcheva V. The TREAT‐NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Human mutation, 2015 Apr; 36(4): 395-402.
  • 3. Gao Q, McNally EM. The Dystrophin Complex: structure, function and implications for therapy. Comprehensive physiology, 2015 Jul 1; 5(3): 1223.
  • 4. Allen DG, Whitehead NP, Froehner SC. Absence of dystrophin disrupts skeletal muscle signaling: roles of Ca2+, reactive oxygen species, and nitric oxide in the development of muscular dystrophy. Physiological reviews, 2016 Jan; 96(1): 253-305.
  • 5. Moat SJ, Bradley DM, Salmon R, Clarke A, Hartley L. Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK). European Journal of Human Genetics, 2013 Oct; 21(10): 1049-53.
  • 6. Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, Case LE, Cripe L, Hadjiyannakis S, Olson AK, Sheehan DW. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. The Lancet Neurology, 2018 Apr 1; 17(4): 347-61..
  • 7. Guiraud S, Aartsma-Rus A, Vieira NM, Davies KE, van Ommen GJ, Kunkel LM. The pathogenesis and therapy of muscular dystrophies. Annual review of genomics and human genetics, 2015 Aug 24; 16(1): 281-308.
  • 8. Huml RA. Muscular dystrophy: historical background and types. In: Huml RA, ed. Muscular Dystrophy. Springer, 2015: 5-7.
  • 9. Ho R, Nguyen ML, Mather P. Cardiomyopathy in Becker muscular dystrophy: overview. World J Cardiol, 2016; 8(6): 356-361. doi:10.4330/wjc.v8.i6.356
  • 10. Hoffman EP. Muscular dystrophy: identification and use of genes for diagnostics and therapeutics. Arch Pathol Lab Med., 1999; 123(11): 1050-1052. doi:10.5858/1999-123-1050-MD
  • 11. Cai A, Kong X. Development of CRISPR-Mediated Systems in the Study of Duchenne Muscular Dystrophy. Hum Gene Ther Methods, 2019 Jun; 30(3): 71-80.
  • 12. Landrum Peay H, Fischer R, Tzeng JP, Hesterlee SE, Morris C, Strong Martin A, Rensch C, Smith E, Ricotti V, Beaverson K, Wand H, Mansfield C. Gene therapy as a potential therapeutic option for Duchenne muscular dystrophy: A qualitative preference study of patients and parents. PLoS One, 2019; 14(5): e0213649.
  • 13. Jones D. Duchenne muscular dystrophy awaits gene therapy. Nat Biotechnol, 2019 Apr; 37(4): 335-337.
  • 14. Hoffman EP, Brown RH Jr, Kunkel LM. "Dystrophin: the protein product of the Duchenne muscular dystrophy locus." Cell, 1987.
  • 15. Ervasti JM, Campbell KP. "A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin." J Cell Biol, 1993.
  • 16. Pereon Y, Mercier S, Magot A. Duchenne muscular dystrophy pathophysiology. Archives de Pediatrie: Organe Officiel de la Societe Francaise de Pediatrie, 2015 Dec 1; 22(12 Suppl 1): 12S18-23.
  • 17. Tidball JG, Wehling-Henricks M. "Evolving therapeutic strategies for Duchenne muscular dystrophy: targeting downstream events." Pediatr Res., 2004.
  • 18. Villalta SA et al. "Immune system modulation in muscular dystrophy." Biochim Biophys Acta., 2010.
  • 19. Bushby K et al. "Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management." Lancet Neurol., 2010.
  • 20. Birnkrant DJ, et al., Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. The Lancet Neurology, 2018; 17(3): 251–267.
  • 21. NIH Genetics Home Reference, Duchenne and Becker muscular, 2023. dystrophy.https://medlineplus.gov/genetics/condition/duchenne-and-becker-muscular-dystrophy.
  • 22. Finder JD, Birnkrant D, Carl J, Farber HJ, Gozal D, Iannaccone ST, et al. Respiratory care of the patient with Duchenne muscular dystrophy: American Thoracic Society consensus statement. Am J Respir Crit Care Med., 2004; 170(4): 456-65.
  • 23. McNally EM, Kaltman JR, Benson DW, Canter CE, Cripe LH, Duan D, et al. Cardiac management of the patient with Duchenne muscular dystrophy. Circulation, 2015; 131(18): 1590-8.
  • 24. Pane M, Lombardo ME, Alfieri P, D'Amico A, Bianco F, Vasco G, et al. Duchenne muscular dystrophy and swallowing difficulties: clinical evaluation and management. Dev Med Child Neurol, 2006; 48(7): 540-5.
  • 25. Banihani R, Smile S, Yoon G, Dupuis A, Mosleh M, Snider A, et al. Cognitive and neurobehavioral profile in boys with Duchenne muscular dystrophy. J Child Neurol, 2015; 30(11): 1472-82.
  • 26. Shimizu-Motohashi Y, Komaki H, Motohashi N, Takeda S, Yokota T, Aoki, Y. Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of Therapeutic Approaches. J Pers Med., 2019; 9.
  • 27. Foundation to Eradicate Duchenne. (n.d.). ReveraGen BioPharma, 2017.
  • 28. Moxley, R. T., III, Ashwal, S., Pandya, S., Connolly, A., Florence, J., Matthews, K., et al.; Quality Standards Subcommittee of the American College of Neurology; Practice Committee of the Child Neurology Society. (2005). Practice parameter: Corticosteroid treatment of Duchenne dystrophy. Neurology, 2020; 64: 13–20.
  • 29. Hanson B, Wood MJA, Roberts TC. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing. RNA Biol, 2021; 18(7): 1048-1062.
  • 30. D'Ambrosio ES, Mendell JR. Evolving therapeutic options for the treatment of Duchenne muscular dystrophy. Neurotherapeutics, 2023; 20(6): 1669-16.